Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)

C. Qvortrup; M. Yilmaz; S. Moller; D. Zitnjak; L. Maltha; M. Krogh; L. Noergaard Petersen; F. Hejlesen; S. B. Winther; K. G. Thomsen; P. Pfeiffer

doi:10.1093/annonc/mdz246.094

Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)

C. Qvortrup, M. Yilmaz, S. Moller, D. Zitnjak, L. Maltha, M. Krogh, L. Noergaard Petersen, F. Hejlesen, S. B. Winther, K. G. Thomsen, P. Pfeiffer

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	617P
Tidsskrift	Annals of Oncology
Vol/bind	30
Udgave nummer	Suppl. 5
Sider (fra-til)	233
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdz246.094
Status	Udgivet - okt. 2019
Begivenhed	44th Congress of the European Society for Medical Oncology - Barcelona, Spanien Varighed: 27. sep. 2019 → 1. okt. 2019

Konference

Konference	44th Congress of the European Society for Medical Oncology
Land	Spanien
By	Barcelona
Periode	27/09/2019 → 01/10/2019

Dokumenter og links

10.1093/annonc/mdz246.094

Citationsformater

Qvortrup, C., Yilmaz, M., Moller, S., Zitnjak, D., Maltha, L., Krogh, M., Petersen, L. N., Hejlesen, F., Winther, S. B., Thomsen, K. G., & Pfeiffer, P. (2019). Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 30(Suppl. 5), 233. [617P]. https://doi.org/10.1093/annonc/mdz246.094

Qvortrup, C. ; Yilmaz, M. ; Moller, S. ; Zitnjak, D. ; Maltha, L. ; Krogh, M. ; Petersen, L. Noergaard ; Hejlesen, F. ; Winther, S. B. ; Thomsen, K. G. ; Pfeiffer, P. / Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC). I: Annals of Oncology. 2019 ; Bind 30, Nr. Suppl. 5. s. 233.

@article{b07a6af7d48e4a049d214b62aa3d8037,

title = "Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)",

author = "C. Qvortrup and M. Yilmaz and S. Moller and D. Zitnjak and L. Maltha and M. Krogh and Petersen, {L. Noergaard} and F. Hejlesen and Winther, {S. B.} and Thomsen, {K. G.} and P. Pfeiffer",

year = "2019",

month = oct,

doi = "10.1093/annonc/mdz246.094",

language = "English",

volume = "30",

pages = "233",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Heinemann",

number = "Suppl. 5",

note = "44th Congress of the European Society for Medical Oncology, ESMO ; Conference date: 27-09-2019 Through 01-10-2019",

}

Qvortrup, C, Yilmaz, M, Moller, S, Zitnjak, D, Maltha, L, Krogh, M, Petersen, LN, Hejlesen, F, Winther, SB, Thomsen, KG & Pfeiffer, P 2019, 'Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)', Annals of Oncology, bind 30, nr. Suppl. 5, 617P, s. 233. https://doi.org/10.1093/annonc/mdz246.094

Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC). / Qvortrup, C.; Yilmaz, M.; Moller, S.; Zitnjak, D.; Maltha, L.; Krogh, M.; Petersen, L. Noergaard; Hejlesen, F.; Winther, S. B.; Thomsen, K. G.; Pfeiffer, P.

I: Annals of Oncology, Bind 30, Nr. Suppl. 5, 617P, 10.2019, s. 233.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)

AU - Qvortrup, C.

AU - Yilmaz, M.

AU - Moller, S.

AU - Zitnjak, D.

AU - Maltha, L.

AU - Krogh, M.

AU - Petersen, L. Noergaard

AU - Hejlesen, F.

AU - Winther, S. B.

AU - Thomsen, K. G.

AU - Pfeiffer, P.

PY - 2019/10

Y1 - 2019/10

U2 - 10.1093/annonc/mdz246.094

DO - 10.1093/annonc/mdz246.094

M3 - Conference abstract in journal

VL - 30

SP - 233

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - Suppl. 5

M1 - 617P

T2 - 44th Congress of the European Society for Medical Oncology

Y2 - 27 September 2019 through 1 October 2019

ER -

Qvortrup C, Yilmaz M, Moller S, Zitnjak D, Maltha L, Krogh M et al. Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology. 2019 okt;30(Suppl. 5):233. 617P. https://doi.org/10.1093/annonc/mdz246.094